C1GALT1C1
Basic information
Region (hg38): X:120625674-120630054
Links
Phenotypes
GenCC
Source:
- hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature (Limited), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature | XL | Allergy/Immunology/Infectious; Cardiovascular; Hematologic; Renal | The condition can involve multi-systemic manifestations, and in addition to managing cardiovascular, infectious, hematologic, and renal complications, medical management (eg, with C5 inhibitor eculizumab) has been described as beneficial | Allergy/Immunology/Infectious; Cardiovascular; Craniofacial; Hematologic; Musculoskeletal; Neurologic | 36599939; 37216524 |
ClinVar
This is a list of variants' phenotypes submitted to
- Atypical hemolytic-uremic syndrome (1 variants)
- Polyagglutinable erythrocyte syndrome (1 variants)
- Hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the C1GALT1C1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 16 | 24 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 2 | 1 | 16 | 8 | 3 |
Variants in C1GALT1C1
This is a list of pathogenic ClinVar variants found in the C1GALT1C1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-120626217-T-C | not specified | Uncertain significance (May 31, 2024) | ||
X-120626227-C-G | Polyagglutinable erythrocyte syndrome • not specified | Uncertain significance (Jan 03, 2024) | ||
X-120626273-T-C | Polyagglutinable erythrocyte syndrome | Likely benign (Nov 02, 2021) | ||
X-120626404-T-C | not specified | Uncertain significance (May 30, 2023) | ||
X-120626412-C-T | not specified | Uncertain significance (Jun 22, 2023) | ||
X-120626501-C-G | Polyagglutinable erythrocyte syndrome • C1GALT1C1-related disorder | Likely benign (Jul 14, 2023) | ||
X-120626505-T-C | Polyagglutinable erythrocyte syndrome | Uncertain significance (Aug 28, 2021) | ||
X-120626531-C-T | Polyagglutinable erythrocyte syndrome | Likely benign (Jul 12, 2022) | ||
X-120626561-A-T | Polyagglutinable erythrocyte syndrome • not specified | Uncertain significance (Dec 15, 2023) | ||
X-120626570-G-C | not specified | Uncertain significance (Jan 26, 2022) | ||
X-120626590-A-G | Polyagglutinable erythrocyte syndrome | Pathogenic (Aug 01, 2008) | ||
X-120626627-A-C | Polyagglutinable erythrocyte syndrome | Pathogenic (-) | ||
X-120626652-G-C | not specified | Uncertain significance (Aug 24, 2023) | ||
X-120626654-G-T | not specified | Uncertain significance (May 08, 2023) | ||
X-120626713-C-T | Polyagglutinable erythrocyte syndrome | Pathogenic (Oct 27, 2005) | ||
X-120626726-C-T | Polyagglutinable erythrocyte syndrome | Likely benign (May 08, 2023) | ||
X-120626727-G-A | Polyagglutinable erythrocyte syndrome | Likely benign (Jan 22, 2024) | ||
X-120626737-G-A | Polyagglutinable erythrocyte syndrome | Uncertain significance (May 20, 2023) | ||
X-120626739-G-A | Polyagglutinable erythrocyte syndrome | Benign (Jan 24, 2024) | ||
X-120626774-A-T | Polyagglutinable erythrocyte syndrome • C1GALT1C1-related disorder | Benign/Likely benign (Jan 31, 2024) | ||
X-120626776-C-T | not specified | Uncertain significance (Mar 29, 2022) | ||
X-120626829-A-G | Polyagglutinable erythrocyte syndrome | Uncertain significance (Jan 04, 2023) | ||
X-120626850-T-C | Polyagglutinable erythrocyte syndrome | Uncertain significance (Nov 27, 2023) | ||
X-120626865-C-T | Polyagglutinable erythrocyte syndrome • C1GALT1C1-related disorder | Benign (Jan 22, 2024) | ||
X-120626901-G-A | Atypical hemolytic-uremic syndrome • Hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature | Pathogenic (Jun 24, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
C1GALT1C1 | protein_coding | protein_coding | ENST00000304661 | 1 | 4358 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.852 | 0.146 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.03 | 84 | 115 | 0.730 | 0.00000798 | 2145 |
Missense in Polyphen | 17 | 34.134 | 0.49804 | 672 | ||
Synonymous | 0.0563 | 38 | 38.4 | 0.988 | 0.00000263 | 568 |
Loss of Function | 2.32 | 0 | 6.26 | 0.00 | 4.50e-7 | 129 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Probable chaperone required for the generation of 1 O- glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins. Probably acts as a specific molecular chaperone assisting the folding/stability of core 1 beta-3-galactosyltransferase (C1GALT1). {ECO:0000269|PubMed:12464682}.;
- Pathway
- Mucin type O-glycan biosynthesis - Homo sapiens (human);Post-translational protein modification;Metabolism of proteins;O-linked glycosylation of mucins;O-linked glycosylation
(Consensus)
Recessive Scores
- pRec
- 0.145
Intolerance Scores
- loftool
- rvis_EVS
- 0.53
- rvis_percentile_EVS
- 80.58
Haploinsufficiency Scores
- pHI
- 0.259
- hipred
- N
- hipred_score
- 0.369
- ghis
- 0.433
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.801
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- C1galt1c1
- Phenotype
- embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- protein O-linked glycosylation;O-glycan processing, core 1;platelet activation;platelet morphogenesis
- Cellular component
- Golgi membrane;integral component of membrane;extracellular exosome
- Molecular function
- protein binding;glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity